Biocartis Group NV has signed a new companion diagnostic (CDx) development agreement with Amgen, aimed at the development of Idylla(TM) CDx biomarker tests for a novel oncology compound to be used in the treatment of certain solid tumors. 

This is the second CDx agreement that Biocartis has signed with Amgen. The first CDx agreement between both companies was announced on December 4, 2017 and aims to register the Idylla(TM) KRAS Mutation Test and the Idylla(TM) NRAS-BRAF Mutation Test with the US Food and Drug Administration (FDA) as a CDx test for Amgen’s drug Vectibix (panitumumab).

Ulrik Cordes, executive vice president of Companion Diagnostics of Biocartis, said, “This new CDx agreement reinforces our strong partnership with Amgen. We are very happy to now add to this relationship a CDx co-development program supporting a novel Amgen drug compound. Today’s announcement is also an important next step in the expansion of our CDx portfolio which should contribute to short term revenue generation and create a strong pipeline of future Idylla(TM) CDx biomarker tests.”